|
1
|
Sung JJ, Lau JY, Goh KL and Leung WK: Asia
Pacific Working Group on Colorectal Cancer: Increasing incidence of
colorectal cancer in Asia: implications for screening. Lancet
Oncol. 6:871–876. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Singapore cancer registry interim report,
. Trends in cancer incidence in Singapore 2007–2011National
Registry of Diseases Office (NRDO). Health Promotion Board;
Singapore: 2011
|
|
3
|
Vecchione L, Jacobs B, Normanno N, et al:
EGFR-targeted therapy. Exp Cell Res. 317:2765–2771. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jonker DJ, O'Callaghan CJ, Karapetis CS,
et al: Cetuximab for the treatment of colorectal cancer. N Engl J
Med. 357:2040–2048. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cunningham D, Humblet Y, Siena S, et al:
Cetuximab monotherapy and cetuximab plus irinotecan in
irinotecan-refractory metastatic colorectal cancer. N Engl J Med.
351:337–345. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Saltz LB, Meropol NJ, Loehrer PJ Sr, et
al: Phase II trial of cetuximab in patients with refractory
colorectal cancer that expresses the epidermal growth factor
receptor. J Clin Oncol. 22:1201–1208. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Karapetis CS, KhambataFord S, Jonker DJ,
et al: K-ras mutations and benefit from cetuximab in advanced
colorectal cancer. N Engl J Med. 359:1757–1765. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
VanCutsem E, Lang I, D'haens G, et al:
Kras status and efficacy in the first-line treatment of patients
with metastatic colorectal cancer (mcrc) treated with folfiri with
or without cetuximab: The crystal experience. J Clin Oncol, 2008
ASCO Annual Meeting Proceedings. 26:22008.
|
|
9
|
VanCutsem E, Köhne CH, Láng I, et al:
Cetuximab plus irinotecan, fluorouracil and leucovorin as
first-line treatment for metastatic colorectal cancer: Updated
analysis of overall survival according to tumor KRAS and BRAF
mutation status. J Clin Oncol. 29:2011–2019. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bokemeyer C, Bondarenko I, Hartmann JT, De
Braud FG, Volovat C, Nippgen J, Stroh C, Celik I and Koralewski P:
Kras status and efficacy of first-line treatment of patients with
metastatic colorectal cancer (mcrc) with folfox with or without
cetuximab: The opus experience. J Clin Oncol. 26 (Suppl
4000):2008.
|
|
11
|
Bokemeyer C, Bondarenko I, Hartmann JT, de
Braud F, Schuch G, Zubel A, Celik I, Schlichting M and Koralewski
P: Efficacy according to biomarker status of cetuximab plus
FOLFOX-4 as first-line treatment for metastatic colorectal cancer:
The OPUS study. Ann Oncol. 22:1535–1546. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Allegra CJ, Jessup JM, Somerfield MR, et
al: American Society of Clinical Oncology provisional clinical
opinion: Testing for KRAS gene mutations in patients with
metastatic colorectal carcinoma to predict response to
anti-epidermal growth factor receptor monoclonal antibody therapy.
J Clin Oncol. 27:2091–2096. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
U.S. Food and Drug Administration, . Class
labeling changes to anti-EGFR monoclonal antibodies, cetuximab
(erbitux) and panitumumab (vectibix). Kras mutations.
2009.http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm172905.htmAccessed
July 15 2013.
|
|
14
|
LaurentPuig P, Cayre A, Manceau G, et al:
Analysis of PTEN, BRAF and EGFR status in determining benefit from
cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin
Oncol. 27:5924–5930. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
DeRoock W, Claes B, Bernasconi D, et al:
Effects of KRAS, BRAF, NRAS and PIK3CA mutations on the efficacy of
cetuximab plus chemotherapy in chemotherapy-refractory metastatic
colorectal cancer: A retrospective consortium analysis. Lancet
Oncol. 11:753–762. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pao W, Miller V, Zakowski M, et al: EGF
receptor gene mutations are common in lung cancers from ‘never
smokers’ and are associated with sensitivity of tumors to gefitinib
and erlotinib. Proc Natl Acad Sci USA. 101:13306–13311. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lynch TJ, Bell DW, Sordella R, et al:
Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer to
gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Eck MJ and Yun CH: Structural and
mechanistic underpinnings of the differential drug sensitivity of
EGFR mutations in non-small cell lung cancer. Biochim Biophys Acta.
1804:559–566. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Takano T, Ohe Y, Sakamoto H, et al:
Epidermal growth factor receptor gene mutations and increased copy
numbers predict gefitinib sensitivity in patients with recurrent
non-small-cell lung cancer. J Clin Oncol. 23:6829–6837. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gao J, Wang TT, Yu JW, Li YY and Shen L:
Wild-type kras and braf could predict response to cetuximab in
chinese colorectal cancer patients. Chin J Cancer Res. 23:271–275.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li FH, Shen L, Li ZH, Luo HY, Qiu MZ,
Zhang HZ, Li YH and Xu RH: Impact of KRAS mutation and PTEN
expression on cetuximab-treated colorectal cancer. World J
Gastroenterol. 16:5881–5888. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mao C, Zhou J, Yang Z, Huang Y, Wu X, Shen
H, Tang J and Chen Q: KRAS, BRAF and PIK3CA mutations and the loss
of PTEN expression in Chinese patients with colorectal cancer. PLoS
One. 7:e366532012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kato S, Iida S, Higuchi T, Ishikawa T,
Takagi Y, Yasuno M, Enomoto M, Uetake H and Sugihara K: PIK3CA
mutation is predictive of poor survival in patients with colorectal
cancer. Int J Cancer. 121:1771–1778. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kimura T, Okamoto K, Miyamoto H, et al:
Clinical benefit of high-sensitivity KRAS mutation testing in
metastatic colorectal cancer treated with anti-EGFR antibody
therapy. Oncology. 82:298–304. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ito Y, Yamada Y, Asada K, Ushijima T,
Iwasa S, Kato K, Hamaguchi T and Shimada Y: EGFR L2 domain mutation
is not correlated with resistance to cetuximab in metastatic
colorectal cancer patients. J Cancer Res Clin Oncol. 139:1391–1396.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nakanishi R, Harada J, Tuul M, Zhao Y,
Ando K, Saeki H, Oki E, Ohga T, Kitao H, Kakeji Y and Maehara Y:
Prognostic relevance of KRAS and BRAF mutations in japanese
patients with colorectal cancer. Int J Clin Oncol. 18:1042–1048.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pang NK, Nga ME, Chin SY, Ismail TM, Lim
GL, Soong R and Salto-Tellez M: KRAS and BRAF mutation analysis can
be reliably performed on aspirated cytological specimens of
metastatic colorectal carcinoma. Cytopathology. 22:358–364. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Moroni M, Veronese S, Benvenuti S,
Marrapese G, SartoreBianchi A, Di Nicolantonio F, Gambacorta M,
Siena S and Bardelli A: Gene copy number for epidermal growth
factor receptor (EGFR) and clinical response to antiEGFR treatment
in colorectal cancer: A cohort study. Lancet Oncol. 6:279–286.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Brevet M, Johnson ML, Azzoli CG and
Ladanyi M: Detection of EGFR mutations in plasma DNA from lung
cancer patients by mass spectrometry genotyping is predictive of
tumor EGFR status and response to EGFR inhibitors. Lung Cancer.
73:96–102. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ruhe JE, Streit S, Hart S, et al: Genetic
alterations in the tyrosine kinase transcriptome of human cancer
cell lines. Cancer Res. 67:11368–11376. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
DiNicolantonio F, Martini M, Molinari F,
et al: Wild-type BRAF is required for response to panitumumab or
cetuximab in metastatic colorectal cancer. J Clin Oncol.
26:5705–5712. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Frattini M, Saletti P, Romagnani E, Martin
V, Molinari F, Ghisletta M, Camponovo A, Etienne LL, Cavalli F and
Mazzucchelli L: PTEN loss of expression predicts cetuximab efficacy
in metastatic colorectal cancer patients. Br J Cancer.
97:1139–1145. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Molinari F, Felicioni L, Buscarino M, et
al: Increased detection sensitivity for KRAS mutations enhances the
prediction of anti-EGFR monoclonal antibody resistance in
metastatic colorectal cancer. Clin Cancer Res. 17:4901–4914. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lièvre A, Bachet JB, Le Corre D, et al:
KRAS mutation status is predictive of response to cetuximab therapy
in colorectal cancer. Cancer Res. 66:3992–3995. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Heinemann V, Stintzing S, Kirchner T,
Boeck S and Jung A: Clinical relevance of EGFR- and KRAS-status in
colorectal cancer patients treated with monoclonal antibodies
directed against the EGFR. Cancer Treat Rev. 35:262–271. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zlobec I, Bihl MP, Schwarb H, Terracciano
L and Lugli A: Clinicopathological and protein characterization of
BRAF- and K-RAS-mutated colorectal cancer and implications for
prognosis. Intl J Cancer. 127:367–380. 2010.
|
|
37
|
Chaiyapan W, Duangpakdee P,
Boonpipattanapong T, Kanngern S and Sangkhathat S: Somatic
mutations of K-ras and BRAF in Thai colorectal cancer and their
prognostic value. Asian Pac J Cancer Prev. 14:329–332. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wu CM, Tang R, Wang JY, Changchien CR and
Hsieh LL: Frequency and spectrum of K-RAS codons 12 and 13
mutations in colorectal adenocarcinomas from Taiwan. Cancer Genet
Cytogenet. 158:55–60. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kim ST, Park KH, Kim JS, Shin SW and Kim
YH: Impact of kras mutation status on outcomes in metastatic colon
cancer patients without anti-epidermal growth factor receptor
therapy. Cancer Res Treat. 45:55–62. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Gallimore AM and Godkin A: Epithelial
barriers, microbiota and colorectal cancer. N Engl J Med.
368:282–284. 2013. View Article : Google Scholar : PubMed/NCBI
|
